Fertility sparing management of endometrial adenocarcinoma and atypical hyperplasia: a literature review

被引:5
|
作者
Koskas, Martin [1 ]
Yazbeck, Chadi [1 ]
Walker, Francine [2 ]
Delorme, Pierre [1 ]
Azria, Elie [1 ]
Luton, Dominique [1 ]
Madelenat, Patrick
机构
[1] Hop Bichat Claude Bernard, Serv Gynecol Obstet & Anatomopathol, F-75877 Paris 18, France
[2] Hop Bichat Claude Bernard, Serv Anatomopathol, F-75018 Paris, France
关键词
conservative management; fertility sparing; adenocarcinoma; atypical hyperplasia; endometrium; YOUNG-WOMEN; CONSERVATIVE TREATMENT; MEDROXYPROGESTERONE ACETATE; PRESERVING TREATMENT; SUCCESSFUL PREGNANCY; PREMENOPAUSAL WOMEN; HORMONE ANALOGS; CARCINOMA; CANCER; PROGESTIN;
D O I
10.1684/bdc.2011.1516
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In endometrial carcinoma (EC) and atypical hyperplasia (AH) diagnosed in childbearing years, the principle of uterine sparing consists in prescription of antigonadotropic treatment to obtain the remission of the endometrial lesion and allow pregnancy, always with a close follow-up looking for progression or persistence of the tumour. Studies evaluating this strategy have suggested the safety of such an approach, but numerous questions remain unanswered, like those concerning the type and the duration of treatment, and the systematic use of Assisted Reproductive Technologies... We performed a critical literature review in order to analyse patients and tumoral characteristics, treatment management and the results of fertility sparing strategy. This review shows that fertility sparing management of AH and intramucous EC permits to obtain pregnancy in one third of candidates. Few disease-related deaths have been reported after this management. One-third of patients experienced progression lesion beyond the endometrium, but generally limited to the myometrium. Progestins have been widely evaluated in this indication and provide an overall remission rate of 80% with a recurrence risk of 25%. triangle
引用
收藏
页码:51 / 60
页数:10
相关论文
共 50 条
  • [41] Comparison among fertility-sparing therapies for well differentiated early-stage endometrial carcinoma and complex atypical hyperplasia
    Zhang, Qing
    Qi, Gonghua
    Kanis, Margaux J.
    Dong, Ruifen
    Cui, Baoxia
    Yang, Xingsheng
    Kong, Beihua
    ONCOTARGET, 2017, 8 (34) : 57642 - 57653
  • [42] Risk Factors for Recurrence in Patients with Atypical Endometrial Hyperplasia and Endometrioid Adenocarcinoma after Fertility-Sparing Treatments
    Yin, Jie
    Ma, Shuai
    Shan, Ying
    Wang, Yongxue
    Li, Yan
    Jin, Ying
    Pan, Lingya
    CANCER PREVENTION RESEARCH, 2020, 13 (04) : 403 - 409
  • [43] Fertility Sparing Treatment in Patients With Early Stage Endometrial Cancer, Using a Combination of Surgery and GnRH Agonist: A Monocentric Retrospective Study and Review of the Literature
    Tock, Stephanie
    Jadoul, Pascale
    Squifflet, Jean-Luc
    Marbaix, Etienne
    Baurain, Jean-Francois
    Luyckx, Mathieu
    FRONTIERS IN MEDICINE, 2018, 5
  • [44] A Turkish Gynecologic Oncology Group study of fertility-sparing treatment for early-stage endometrial cancer
    Dursun, Polat
    Erkanli, Serkan
    Guzel, Ahmet Baris
    Gultekin, Murat
    Tarhan, Nefise Cagla
    Altundag, Ozden
    Demirkiran, Fuat
    Bese, Tugan
    Yildirim, Yusuf
    Bozdag, Gurkan
    Yarali, Hakan
    Simsek, Tayyup
    Ozcelik, Bulent
    Ortac, Firat
    Taskin, Salih
    Guvenal, Tevfik
    Ozgul, Nejat
    Haberal, Ali
    Vardar, M. Ali
    Dede, Murat
    Yenen, Mufit
    Altintas, Aytekin
    Arvas, Macit
    Ayhan, Ali
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2012, 119 (03) : 270 - 273
  • [45] Impact of obesity on the results of fertility-sparing management for atypical hyperplasia and grade 1 endometrial cancer
    Gonthier, Clementine
    Walker, Francine
    Luton, Dominique
    Yazbeck, Chadi
    Madelenat, Patrick
    Koskas, Martin
    GYNECOLOGIC ONCOLOGY, 2014, 133 (01) : 33 - 37
  • [46] The fertility-sparing treatment in patients with endometrial atypical hyperplasia and early endometrial cancer: A debated therapeutic option
    Gadducci, Angiolo
    Spirito, Nicoletta
    Baroni, Elena
    Tana, Roberta
    Genazzani, Andrea Riccardo
    GYNECOLOGICAL ENDOCRINOLOGY, 2009, 25 (10) : 683 - 691
  • [47] Oncologic, fertility, and obstetric outcomes with MPA therapy in women with endometrial cancer and atypical endometrial hyperplasia
    Takeda, Asuka
    Yamamoto, Yuri
    Tamura, Kou
    Aoki, Hidenori
    Noguchi, Hiroki
    Minato, Saki
    Kamada, Shuhei
    Arakaki, Ryosuke
    Kaji, Takashi
    Iwasa, Takeshi
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2024, 50 (04) : 633 - 638
  • [48] Use of clinicopathological factors to predict prognosis of fertility-sparing treatment for endometrial endometrioid carcinoma and atypical hyperplasia
    Zhang, Xiaobo
    Zhao, Xiaoya
    Wang, Chen
    Lu, Shanshan
    Wang, Yiqin
    He, Yijiao
    Wang, Jianliu
    Shen, Danhua
    ONCOLOGY LETTERS, 2023, 25 (02)
  • [49] Outcome of fertility-sparing treatment with medroxyprogesterone acetate for atypical hyperplasia and endometrial carcinoma in young Japanese women
    Kataoka, H.
    Mori, T.
    Yamamoto, T.
    Sawada, M.
    Kuroboshi, H.
    Tatsumi, H.
    Iwasaku, K.
    Kitawaki, J.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2014, 35 (01) : 11 - 15
  • [50] Trends and characteristics of fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer in Japan: a survey by the Gynecologic Oncology Committee of the Japan Society of Obstetrics and Gynecology
    Ushijima, Kimio
    Tsuda, Naotake
    Yamagami, Wataru
    Mitsuhashi, Akira
    Mikami, Mikio
    Yaegashi, Nobuo
    Enomoto, Takayuki
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2023, 34 (03)